Acesion Pharma, a pharmaceutical company developing novel first-in-class drugs to treat atrial fibrillation (AF), announced today that it has appointed Christina Sylvest, MSc Pharm, as Senior Vice President Acute Cardioversion.
Christina Sylvest has a track record of driving successful clinical development and development programmes. Her appointment comes as Acesion accelerates the preclinical development of its first development candidate for the acute cardioversion of AF.
Christina Sylvest has more than 20 years experience of clinical operations and project management leading global and local Phase I-IV clinical programmes with accountability to CEOs and Boards of Directors. Prior to joining Acesion, Sylvest was responsible for Veloxis Pharmaceuticals A/S (previously Life Cycle Pharma A/S) Phase I-IV clinical operational activities both in Europe and in the US. Prior to Veloxis, Sylvest worked in various management roles in clinical development at Rheoscience A/S, Novo Nordisk A/S and Ferring Pharmaceuticals A/S.
Frans Wuite, CEO of Acesion Pharma commented:
"We are delighted to welcome Christina to the company at a pivotal time in its evolution. We will soon progress our first development candidate for acute cardioversion of atrial fibrillation and our focus now is to move this programme forward towards human clinical evaluation. Christina will spearhead the progress of our programme in acute cardioversion as Acesion enters this exciting phase of rapid development."
Acesion’s development candidates have shown early promise in a number of animal studies demonstrating that they are effective anti-arrhythmics that act rapidly in bringing the heart from AF back to normal heart rhythm.